These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28933663)

  • 1. Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform.
    MacDonald LD; MacKay A; Kaliaperumal V; Weir G; Penwell A; Rajagopalan R; Langley JM; Halperin S; Mansour M; Stanford MM
    Hum Vaccin Immunother; 2018 Jan; 14(1):59-66. PubMed ID: 28933663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented With a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study.
    Langley JM; MacDonald LD; Weir GM; MacKinnon-Cameron D; Ye L; McNeil S; Schepens B; Saelens X; Stanford MM; Halperin SA
    J Infect Dis; 2018 Jul; 218(3):378-387. PubMed ID: 29617814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant.
    Langley JM; Aggarwal N; Toma A; Halperin SA; McNeil SA; Fissette L; Dewé W; Leyssen M; Toussaint JF; Dieussaert I
    J Infect Dis; 2017 Jan; 215(1):24-33. PubMed ID: 27694633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.
    Lambert SL; Aslam S; Stillman E; MacPhail M; Nelson C; Ro B; Sweetwood R; Lei YM; Woo JC; Tang RS
    PLoS One; 2015; 10(3):e0119509. PubMed ID: 25793508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.
    Langley JM; Sales V; McGeer A; Guasparini R; Predy G; Meekison W; Li M; Capellan J; Wang E
    Vaccine; 2009 Sep; 27(42):5913-9. PubMed ID: 19651171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
    Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine.
    Huang Y; Cyr SL; Burt DS; Anderson R
    J Clin Virol; 2009 Apr; 44(4):287-91. PubMed ID: 19233722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
    Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE
    Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alum Adjuvant Enhances Protection against Respiratory Syncytial Virus but Exacerbates Pulmonary Inflammation by Modulating Multiple Innate and Adaptive Immune Cells.
    Kim KH; Lee YT; Hwang HS; Kwon YM; Jung YJ; Lee Y; Lee JS; Lee YN; Park S; Kang SM
    PLoS One; 2015; 10(10):e0139916. PubMed ID: 26468884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the protective potential of antibody and T cell responses elicited by a novel preventative vaccine towards respiratory syncytial virus small hydrophobic protein.
    Torrey HL; Kaliaperumal V; Bramhecha Y; Weir GM; Falsey AR; Walsh EE; Langley JM; Schepens B; Saelens X; Stanford MM
    Hum Vaccin Immunother; 2020 Sep; 16(9):2007-2017. PubMed ID: 32530723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice.
    Cayatte C; Snell Bennett A; Rajani GM; Hostetler L; Maynard SK; Lazzaro M; McTamney P; Ren K; O'Day T; McCarthy MP; Schneider-Ohrum K
    PLoS One; 2017; 12(11):e0188708. PubMed ID: 29182682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.
    August A; Glenn GM; Kpamegan E; Hickman SP; Jani D; Lu H; Thomas DN; Wen J; Piedra PA; Fries LF
    Vaccine; 2017 Jun; 35(30):3749-3759. PubMed ID: 28579233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with an adjuvanted low-energy electron irradiation inactivated respiratory syncytial virus vaccine shows immunoprotective activity in mice.
    Bayer L; Fertey J; Ulbert S; Grunwald T
    Vaccine; 2018 Mar; 36(12):1561-1569. PubMed ID: 29439869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals.
    Falsey AR; Walsh EE; Capellan J; Gravenstein S; Zambon M; Yau E; Gorse GJ; Edelman R; Hayden FG; McElhaney JE; Neuzil KM; Nichol KL; Simões EA; Wright PF; Sales VM
    J Infect Dis; 2008 Nov; 198(9):1317-26. PubMed ID: 18855558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques.
    Patton K; Aslam S; Shambaugh C; Lin R; Heeke D; Frantz C; Zuo F; Esser MT; Paliard X; Lambert SL
    Vaccine; 2015 Aug; 33(36):4472-8. PubMed ID: 26206269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
    Kamphuis T; Shafique M; Meijerhof T; Stegmann T; Wilschut J; de Haan A
    Vaccine; 2013 Apr; 31(17):2169-76. PubMed ID: 23499594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The respiratory syncytial virus fusion protein formulated with a polymer-based adjuvant induces multiple signaling pathways in macrophages.
    Sarkar I; Garg R; van Drunen Littel-van den Hurk S
    Vaccine; 2018 Apr; 36(17):2326-2336. PubMed ID: 29559168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles.
    Garlapati S; Garg R; Brownlie R; Latimer L; Simko E; Hancock RE; Babiuk LA; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Vaccine; 2012 Jul; 30(35):5206-14. PubMed ID: 22713718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunopathology of RSV infection: prospects for developing vaccines without this complication.
    van Drunen Littel-van den Hurk S; Mapletoft JW; Arsic N; Kovacs-Nolan J
    Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.